We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-14.15%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.67B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
2.74%
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$87.4M
2
BLU
BELLUS Health Inc.
BLU
+$67.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$59.2M
4
RLMD icon
Relmada Therapeutics
RLMD
+$44.5M
5
XLO icon
Xilio Therapeutics
XLO
+$34.1M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$190M
2
TGTX icon
TG Therapeutics
TGTX
+$49M
3
VERV
Verve Therapeutics
VERV
+$23.9M
4
CTMX icon
CytomX Therapeutics
CTMX
+$17.8M
5
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Financials 0.78%
3 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
76
Bolt Biotherapeutics
BOLT
$7.76M
$11.7M 0.21%
118,916
– –
OTIC
77
DELISTED
Otonomy, Inc.
OTIC
$11.6M 0.21%
5,600,000
+3,968,365
+243% +$8.15M
SPRY icon
78
ARS Pharmaceuticals
SPRY
$423M
$11.6M 0.2%
1,742,186
– –
VERV
79
DELISTED
Verve Therapeutics
VERV
$11.4M 0.2%
310,284
-570,000
-65% -$23.9M
RNAM
80
DELISTED
Avidity Biosciences
RNAM
$10.1M 0.18%
423,616
– –
HLTH
81
DELISTED
Cue Health Inc. Common Stock
HLTH
$10.1M 0.18%
750,000
– –
FLACU
82
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$9.92M 0.17%
1,000,000
– –
ARYE
83
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$9.7M 0.17%
1,000,000
– –
CNCE
84
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.56M 0.17%
3,033,603
– –
IMA
85
ImageneBio Inc
IMA
$55.8M
$9.4M 0.17%
62,500
– –
COGT icon
86
Cogent Biosciences
COGT
$5.68B
$8.8M 0.16%
1,025,641
– –
PHAS
87
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$7.44M 0.13%
2,850,000
– –
FVAM
88
DELISTED
5:01 Acquisition Corp
FVAM
$7.39M 0.13%
750,000
– –
ATXS
89
DELISTED
Astria Therapeutics
ATXS
$6.8M 0.12%
1,262,193
– –
ENTX icon
90
Entera Bio
ENTX
$495M
$6.62M 0.12%
2,353,000
– –
OBIO icon
91
Orchestra BioMed
OBIO
$363M
$6.3M 0.11%
625,000
– –
CMPX icon
92
Compass Therapeutics
CMPX
$333M
$5.86M 0.1%
+1,849,518
New +$6.13M
TCRX icon
93
TScan Therapeutics
TCRX
$21.8M
$5.65M 0.1%
1,255,317
– –
CGEM icon
94
Cullinan Oncology
CGEM
$1.32B
$5.4M 0.1%
350,000
– –
BMEA icon
95
Biomea Fusion
BMEA
$130M
$3.73M 0.07%
500,000
– –
CVRX icon
96
CVRx
CVRX
$79.9M
$3.36M 0.06%
275,000
– –
SYRS
97
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.93M 0.05%
90,000
– –
AVIR icon
98
Atea Pharmaceuticals
AVIR
$419M
– –
-5,427,655
Closed -$190M
CTMX icon
99
CytomX Therapeutics
CTMX
$586M
– –
-3,500,000
Closed -$17.8M
MLTX icon
100
MoonLake Immunotherapeutics
MLTX
$1.04B
– –
-700,000
Closed -$6.96M
1 2 3
4
5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, RA Capital Management held 105 positions worth $5.67B, down 21% from $7.22B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management's Q4 2021 filing shows 10 new, 9 increased, 7 reduced and 8 closed positions. Its largest new stake was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M. The largest sale was Atea Pharmaceuticals, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q4 2021 buy was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q4 2021, an estimated $26.8M increase.
  • RA Capital Management's biggest Q4 2021 reduction was TG Therapeutics, cutting an estimated $49M.
  • RA Capital Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $190M.
  • RA Capital Management's ten largest holdings make up 45% of its $5.67B portfolio in Q4 2021.
  • RA Capital Management opened 10 new positions and closed 8 in Q4 2021.
  • RA Capital Management's portfolio value fell 21% quarter-over-quarter to $5.67B.

Based on RA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.